Monthly Archives: August 2014

Takeaways from Seattle Summer 2014 Seminars

A guest post by Donald Chisum and Janice Mueller. In August 2014 the Chisum Patent Academy held two back-to-back seminars in its Seattle, Washington facility to discuss and debate current developments in patent law. Each roundtable seminar group was limited … Continue reading

Posted in Conferences and Classes | Tagged , , , , , , | Leave a comment

FDA’s New Biosimilars Guidance

The following has been posted with the permission of their authors James E. Valentine and James C. Shehan of Hyman, Phelps & McNamara as part of their FDA Law Blog. *** August 09, 2014 FDA’s New Biosimilars Guidance Has Sponsors … Continue reading

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , , | Leave a comment

Fed. Cir.: Antitrust Issues Can Arise From Hatch-Waxman Litigation

In Tyco Healthcare Group v. Mutual Pharm. Co., App. no. 13-1386 (Fed. Cir. August 6, 2014), a divided panel of the court reversed a district court’s summary judgment ruling dismissing antitrust charges brought by ANDA filer Mutual against patent-holder Tyco. (A … Continue reading

Posted in Antitrust Issues | Tagged , , , , , , , , | Leave a comment

Ignorance is Bliss – for Teva

I did not pay much attention to the fairly recent panel decision in Bristol-Myers Squibb Co. v. Teva Pharma. USA, 757 F.3d 967 (Fed. Cir. 2014). It seemed like a fairly routine panel affirmance of the district court’s finding that … Continue reading

Posted in Obviousness | Tagged , , , , , , , , , , , | 1 Comment